Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03102710 · ClinicalTrials.gov registry record · NA
Neuromodulation of Lidocaine and Capsaicin Cream Effects on Pain Experience
A NA study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- NA
- Development phase
- 103
- Enrollment target
NCT03102710: Completed NA study, sponsored by Massachusetts General Hospital.
NCT03102710 is a NA study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 103 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03102710, a NA study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- NA
- Development phase
- 103 participants
- Enrollment target
Study Summary
The aim of this study is to use a brain stimulation tool called transcranial direct current stimulation (tDCS) to investigate the analgesic (reducing sensitivity to pain) effects of lidocaine cream and the hyperalgesic (increasing sensitivity to pain) effects of capsaicin cream using a neutral cream as a control. tDCS stimulation has been shown to temporarily influence the way the stimulated part of the brain functions. With this method, the involvement of specific parts of the brain can be investigated in the working of the brain as a whole.
Interventions
- DEVICE transcranial direct current stimulation (tDCS)
- OTHER Lidocaine cream
- OTHER Capsaicin cream
- OTHER Control cream
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 103 participants |
| Start Date | 2016-05 |
| Est. Completion | 2019-03 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03102710
The ClinicalTrials.gov registry entry for NCT03102710 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 103 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which transcranial direct current stimulation (tDCS) is the first listed.
NCT03102710 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03102710 about?
NCT03102710 is a clinical study titled "Neuromodulation of Lidocaine and Capsaicin Cream Effects on Pain Experience". The aim of this study is to use a brain stimulation tool called transcranial direct current stimulation (tDCS) to investigate the analgesic (reducing sensitivity to pain) effects of lidocaine cream and the hyperalgesic (increasing sensitivity to pain) effects of capsaicin cream using a neutral cream...
What is the current status of trial NCT03102710?
This trial is currently completed. It is a NA study. The enrollment target is 103 participants. The study started on 2016-05. Estimated completion is 2019-03.
What interventions are being tested in trial NCT03102710?
The interventions under investigation include: transcranial direct current stimulation (tDCS) (DEVICE), Lidocaine cream (OTHER), Capsaicin cream (OTHER), Control cream (OTHER).
Who is sponsoring clinical trial NCT03102710?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.